Drug Information

Drug General Information
Drug ID
D03PKJ
Former ID
DIB008647
Drug Name
MK-6186
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Phase 1 [523090]
Company
Merck & Co Inc
Formula
C21H12Cl2N6O
Canonical SMILES
Clc1cc(Oc2c(Cl)ccc3c2cnn3Cc4n[nH]c5ncccc45)cc(c1)C#N
InChI
1S/C21H12Cl2N6O/c22-13-6-12(9-24)7-14(8-13)30-20-16-10-26-29(19(16)4-3-17(20)23)11-18-15-2-1-5-25-21(15)28-27-18/h1-8,10H,11H2,(H,25,27,28)
InChIKey
FZBAOOQVQXATRL-UHFFFAOYSA-N
PubChem Compound ID
24988948
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Inhibitor [531832]
References
Ref 523090ClinicalTrials.gov (NCT01152255) MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2). U.S. National Institutes of Health.
Ref 531832Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.